At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 206 enrolled
Drug / intervention
VOLUX XC +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Evaluator-blinded, Randomized, Parallel-group, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition
In Brief
A Phase 3 clinical trial evaluating VOLUX XC and No-treatment control for Jawline Definition. Completed, enrolled 206 participants across 19 sites.
Detailed Summary
This study will evaluate the safety and effectiveness of JUVÉDERM VOLUX™ XC injectable gel for restoring jawline definition
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJawline Definition
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedOct 2018
Enrollment StartNov 2018
Primary CompletionFeb 2020
Study CompletionJan 2021
TodayJul 2026
First PostedOct 19, 2018
Enrollment StartNov 12, 2018
Primary CompletionFeb 4, 2020
Study CompletionJan 26, 2021
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.7 years ago
Interventions
VOLUX XCdevice
Participants will be treated with VOLUX XC hyaluronic acid (HA) injectable gel on day 1 with optional touch-up at day 30 and optional maintenance treatment at Month 12.
No-treatment controlother
No-treatment during the control period. Optional delayed-treatment with VOLUX XC (initial with optional touch-up) at the beginning of the Post-Control period.